Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Teva
UBS
Deloitte
Colorcon

Generated: June 18, 2019

DrugPatentWatch Database Preview

Liebel-flarsheim Company Profile

« Back to Dashboard

What is the competitive landscape for LIEBEL-FLARSHEIM, and what generic and branded alternatives to LIEBEL-FLARSHEIM drugs are available?

LIEBEL-FLARSHEIM has eleven approved drugs.



Summary for Liebel-flarsheim
US Patents:0
Tradenames:14
Ingredients:5
NDAs:11

Drugs and US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride INJECTABLE;INJECTION 021569-001 Jul 27, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-002 Dec 8, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim CONRAY 43 iothalamate meglumine INJECTABLE;INJECTION 013295-002 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim CONRAY iothalamate meglumine INJECTABLE;INJECTION 013295-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 5,137,711 ➤ Try a Free Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 4,396,598 ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-002 Dec 8, 1999 5,137,711 ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 5,130,120 ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 5,130,120 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Argus Health
Queensland Health
McKesson
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.